Director/PDMR Shareholding

Summary by AI BETAClose X

Spire Healthcare Group plc announced on March 18, 2026, that executive directors Justin Ash and Harbant Samra were granted nil cost options under the Long Term Incentive Plan on March 17, 2026. Justin Ash received an award for up to 736,733 ordinary shares, and Harbant Samra received an award for up to 451,653 ordinary shares, with both awards representing 200% of their current base salary. The actual number of shares vesting will depend on performance conditions set to be finalized and published later, with a share price of 185.08 pence used for the award calculation, and a further two-year holding period will apply post-vesting.

Disclaimer*

Spire Healthcare Group PLC
18 March 2026
 

Spire Healthcare Group plc (the Company)

Notification of Transactions of Persons Discharging Managerial Responsibilities

 

18 March 2026

 

Grant of Long Term Incentive Plan (LTIP) awards

The Company announces that, on 17 March 2026, performance share awards were granted over the Company's ordinary shares in the form of nil cost options to the following Executive Directors of the Company, under the rules of the Company's Long Term Incentive Plan.

 

Executive Director                Maximum number of shares under award

Justin Ash                               736,733

Harbant Samra                       451,653

 

The number of shares set out above represents 200% of current base salary. It is the maximum number which may vest under the LTIP awards following the end of the performance period (31 December 2028).  The shareholder-approved Remuneration Policy permits awards of up to 200% of base salary for Executive Directors.

 

The actual number of shares which vest will depend on the extent to which the relevant performance conditions have been satisfied.

 

Given the current evaluation of actions to drive shareholder value, the Remuneration Committee is taking further time to carefully consider and determine the LTIP performance conditions and targets to ensure they are fully aligned to the Company's forward-looking strategy. Once finalised, the 2026 LTIP performance conditions and targets will be published on the Company's website, and they will be disclosed in the 2026 Directors' Remuneration Report.

 

The share price used to determine the number of shares under the LTIP Awards was 185.08 pence, being the average of the mid-market closing share price over the five trading days ending on 16 March 2026.

 

 

Notes:

 

1)   For both Executive Directors the 2026 LTIP awards described above will also be subject to a further two-year holding period following the vesting date.

2)   The actual number of shares which vest under the LTIP awards will depend on the extent to which the relevant performance conditions are satisfied in due course.

Name of contact and telephone number for queries:

Mantraraj Budhdev

Group General Counsel, Chief People Officer and Company Secretary

Spire Healthcare Group plc

Tel: 07787 283848

 

 

 



 

Notification and public disclosure of transaction by persons discharging managerial responsibility and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Justin Ash

2

Reason for the notification

a)

Position/status

 

Chief Executive Officer

b)

Initial notification /Amendment

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 

Spire Healthcare Group plc

b)

LEI

213800IBJPW3SE2RA350

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 1 pence each

 

GB00BNLPYF73

b)

Nature of the transaction

Grant of performance share awards under the Company's Long Term Incentive Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

 

Nil

736,733

 

 

d)

Aggregated information

- Aggregated volume

- Price

As above

e)

Date of the transaction

2026-03-17

f)

Place of the transaction

Outside of trading venue

 

a)

Name

 

Harbant Samra

2

Reason for the notification

a)

Position/status

 

Chief Financial Officer

b)

Initial notification /Amendment

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 

Spire Healthcare Group plc

b)

LEI

213800IBJPW3SE2RA350

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 1 pence each

 

GB00BNLPYF73

b)

Nature of the transaction

Grant of performance share awards under the Company's Long Term Incentive Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

 

Nil

451,653

 

 

d)

Aggregated information

- Aggregated volume

- Price

As above

e)

Date of the transaction

2026-03-17

f)

Place of the transaction

Outside of trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100